Panbela Therapeutics Total Assets 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$142.2B
Bristol Myers Squibb (BMY)	$117.1B
Gilead Sciences (GILD)	$117.1B
Vertex Pharmaceuticals (VRTX)	$105.1B
CSL (CSLLY)	$85.9B
Regeneron Pharmaceuticals (REGN)	$78.5B
GSK (GSK)	$70.5B
Argenex SE (ARGX)	$38B
Alnylam Pharmaceuticals (ALNY)	$31.4B
BioNTech SE (BNTX)	$27.4B
Biogen (BIIB)	$21.7B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$17.7B
Moderna (MRNA)	$15.5B
Genmab (GMAB)	$13.5B
Incyte (INCY)	$13.5B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.6B
Sarepta Therapeutics (SRPT)	$11.6B
Bio-Techne Corp (TECH)	$11.6B
Exact Sciences (EXAS)	$10.8B
Vaxcyte (PCVX)	$10.7B
QIAGEN (QGEN)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$9B
Roivant Sciences (ROIV)	$8.7B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8.2B